GC Cell Corp
KOSDAQ:144510
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (0.9), the stock would be worth ₩14 857.87 (37% downside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.4 | ₩23 750 |
0%
|
| 3-Year Average | 0.9 | ₩14 857.87 |
-37%
|
| 5-Year Average | 1.1 | ₩18 085.93 |
-24%
|
| Industry Average | 5.6 | ₩91 582.81 |
+286%
|
| Country Average | 0.8 | ₩13 605.09 |
-43%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
G
|
GC Cell Corp
KOSDAQ:144510
|
356.9B KRW | 1.4 | -1.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -1 260 263.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 4.5 | 87.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 3.6 | 22.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 3.7 | 19.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 966.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 7.3 | 27.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 5.6 | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 14.8 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.8 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 1.5 | 29.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.5 |
| Median | 0.8 |
| 70th Percentile | 1.7 |
| Max | 2 224.6 |
Other Multiples
GC Cell Corp
Glance View
GC Cell Corp. engages in the research and development of cell curing agents and in the transport and sale of consignment inspection samples. The company is headquartered in Yongin, Gyeonggi-Do. The company went IPO on 2016-06-23. The firm operates its business through four segments. The Specimen Testing Service segment provides sample testing services, clinical trial services, and veterinary testing services. The Cell Therapy segment is engaged in cell culture and technology transfer business. The Cord Blood Storage segment is engaged in the cord blood storage business. The Other Business segment is engaged in bio-logistics business and others.
